Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Marinus Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MRNS
Nasdaq
8731
https://marinuspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Marinus Pharmaceuticals Inc
Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study
- Apr 16th, 2024 3:46 pm
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
- Apr 15th, 2024 4:54 pm
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
- Apr 15th, 2024 11:00 am
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Apr 5th, 2024 8:00 pm
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
- Mar 27th, 2024 12:41 pm
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
- Mar 20th, 2024 2:32 pm
Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results
- Mar 7th, 2024 6:41 pm
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 4:10 pm
Q4 2023 Marinus Pharmaceuticals Inc Earnings Call
- Mar 6th, 2024 12:14 pm
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
- Mar 5th, 2024 10:10 pm
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 5th, 2024 9:01 pm
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
- Feb 21st, 2024 12:00 pm
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
- Feb 20th, 2024 12:00 pm
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
- Feb 6th, 2024 11:19 am
Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment
- Jan 31st, 2024 1:13 am
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
- Jan 22nd, 2024 2:56 pm
Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet
- Jan 17th, 2024 2:55 pm
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
- Jan 4th, 2024 12:01 pm
Those who invested in Marinus Pharmaceuticals (NASDAQ:MRNS) a year ago are up 156%
- Jan 2nd, 2024 10:08 am
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
- Nov 20th, 2023 9:01 pm
Scroll